PUBLIC COMPANY
savePrevail Therapeutics Inc
updated 2mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
- phase1A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
- phase2Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)
- phase2Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
- phase2Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
🐶 Hiring Signal
News
- Lilly drops another gene therapy trial from $1B Prevail buyoutEli Lilly has axed another trial of a gene therapy acquired in its $1 billion Prevail Therapeutics buyout, further denting the drugmaker’s chances of delivering a return on its investment.fiercebiotech · 9d ago
comments(0)
5-min edit window · permanent after that